Skip to main content
Clinical Trials/DRKS00033783
DRKS00033783
Recruiting
Phase 1

Study on the efficiacy of an app-based intervention in patients with axial spondyloarthritis. - Bechterew-App Study 1

niversitätsklinikum Würzburg, Medizinische Klinik II, Rheumatologie/ Klinische Immunologie0 sites200 target enrollmentStarted: March 1, 2024Last updated:

Overview

Phase
Phase 1
Status
Recruiting
Sponsor
niversitätsklinikum Würzburg, Medizinische Klinik II, Rheumatologie/ Klinische Immunologie
Enrollment
200

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to one (—)
Sex
All

Inclusion Criteria

  • Clinically confirmed axSpA and regular connection to an appropriate specialist physician
  • Stable therapy situation
  • BASDAI score of \= 3\.5 in the screening questionnaire
  • Referring to the past 4 weeks on average:
  • Maximum of 4 times per week independent execution of axSpA\-specific exercises at home, totaling a maximum of 50 minutes per week
  • Maximum of 3 times per week regular participation in sports (including strength training, endurance sports, team sports, yoga, pilates, and other sports), group gymnastics, or functional training, totaling a maximum of 90 minutes.
  • Referring to the last 3 months before study enrollment, on average, a maximum of 1 session per week of individual physiotherapy with no planned increase during the study
  • Sufficient proficiency in the German language
  • Ownership of an Android or iOS\-compatible smartphone with mobile internet access, meeting the necessary requirements for using the Bechterew app
  • Adequate smartphone competence

Exclusion Criteria

  • Lack of capacity to consent
  • Current pregnancy
  • Conditions that could pose a risk for increased exercise training. These include particularly advanced heart failure (NYHA 3/4\), angina pectoris, severe COPD GOLD 3/4\), peripheral arterial occlusive disease (pAVK) \= Grade II B, obesity from Grade III onwards, active infectious diseases, acute malignant disease, status post myocardial infarction within the last 24 weeks prior to study enrollment, movement\-limiting neurological diseases, acute orthopedic injury (e.g., fracture, ligament strain), status post limb amputation, ongoing or planned chemotherapy or radiation therapy (non\-exhaustive list)
  • Study participant is unable to engage in daily exercise due to other health restrictions not mentioned in Chapter 8\.3\.2
  • Presence of an absolute contraindication to app usage as per manufacturer instructions
  • Current active use of another smartphone app for the therapy of axSpA

Investigators

Sponsor
niversitätsklinikum Würzburg, Medizinische Klinik II, Rheumatologie/ Klinische Immunologie

Similar Trials